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Abstract
It is widely acknowledged that new regimens are urgently needed for the treatment of tuberculosis. The primary endpoint
in the Phase III trials is a composite outcome of failure at the end of treatment or relapse after stopping treatment. Such
trials are usually both long and expensive. Valid surrogate endpoints measured during or at the end of treatment could
dramatically reduce both the time and cost of assessing the effectiveness of new regimens. The objective of this study was
to evaluate sputum culture results on solid media during treatment as surrogate endpoints for poor outcome. Data were
obtained from twelve randomised controlled trials conducted by the British Medical Research Council in the 1970s and 80s
in East Africa and East Asia, consisting of 6974 participants and 49 different treatment regimens. The month two culture
result was shown to be a poor surrogate in East Africa but a good surrogate in Hong Kong. In contrast, the month three
culture was a good surrogate in trials conducted in East Africa but not in Hong Kong. As well as differences in location,
ethnicity and probable strain of Mycobacteria tuberculosis, Hong Kong trials more often evaluated regimens with rifampicin
throughout and intermittent regimens, and patients in East African trials more often presented with extensive cavitation
and were slower to convert to culture negative during treatment. An endpoint that is a summary measure of the
longitudinal profile of culture results over time or that is able to detect the presence of M. tuberculosis later in treatment is
more likely to be a better endpoint for a phase II trial than a culture result at a single time point and may prove to be an
acceptable surrogate. More data are needed before any endpoint can be used as a surrogate in a confirmatory phase III trial.
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Introduction
Tuberculosis (TB) is one of the world’s oldest infectious disease
and over the centuries has been responsible for more mortality,
morbidity and human suffering that any other[1]. Though an
effective cure is available today for no more than US $20, it is
estimated that there are over 9 million new cases and almost 2
million people die every year from TB[2]. The six month standard
regimen for drug-susceptible TB has been shown to be highly
efficacious in clinical trials[3], but such results are rarely achieved
in practice[4]. New treatment regimens are urgently needed to
reduce the duration of treatment for drug-susceptible TB and
effectively treat multi-drug resistant TB (MDR-TB).
TB is almost unique among bacterial infections in that failure to
culture the bacilli is not necessarily indicative of cure. An effective
regimen is one which renders patients culture negative by the end
of treatment, but also prev_ENREF_5ents subsequent relapse.
Clinical trials to evaluate new regimens for the treatment of TB
therefore commonly involve follow-up beyond the end of
treatment of 18–24 months[5]. A surrogate endpoint measured
during or at the end of treatment could be used as a substitute for
the currently used composite clinical endpoint of treatment failure
and relapse in a phase III clinical trial[5] thereby substantially
shortening the trial duration and speeding overall drug develop-
ment.
A biomarker is any marker ‘objectively measured and evaluated
as an indicator of normal biological processes, pathogenic
processes, or pharmacologic responses to a therapeutic interven-
tion’[6]. A surrogate endpoint is a biomarker that fully captures the
effect of the trial intervention on the clinical endpoint and ‘for
which a test of the null hypothesis of no relationship to the
treatment groups under comparison is also a valid test of the
corresponding null hypothesis based on the true [clinical]
endpoint’[7]. Such an endpoint can only be defined in the context
of a comparison of different treatment arms in a randomised
controlled trial. _ENREF_7One of the most important principles
for evaluating a putative surrogate is that mere correlation does
not imply surrogacy[8,9].
There have been several reviews on surrogate endpoints and
biomarkers of TB treatment response[10–12]_ENREF_8. Perrin
et al.[10] summarised the potential markers currently available
that could describe a patient’s response to treatment (biomarkers of
treatment response) but no formal evaluation of surrogate endpoints
was provided. The two month culture was shown to be a risk
factor for relapse in two trials[13,14] but there was, however, no
attempt to formally evaluate the endpoint as a surrogate endpoint.
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Perrin et al. also referred to a review by Mitchison[15]
expanding on earlier correspondence[16] which addressed the
relationship between relapse rates and rates of culture positivity
across several clinical trials. It is not clear which statistical methods
were used; the results indicate a relationship suggestive of
surrogacy, but with a note of caution that ‘the most effective time
for measuring sputum conversion may vary according to the drug
under test.’[15] The report from an expert consultation meeting
on biomarkers in TB organised by WHO Tropical Disease
Research (TDR) also identified the two month culture result as
being currently accepted as a surrogate for treatment outcome, but
again without any formal evaluation to support this[17]. A recent
systematic review of sputum monitoring during TB treatment for
predicting outcome found the two month culture had modest
specificity but low sensitivity for predicting failure and relapse [18].
The objective of the present study was to evaluate sputum
culture results during treatment as potential surrogate endpoints
for long term outcome in the treatment of pulmonary TB using
appropriate statistical methodology. Treatment comparisons are
required for evaluating a surrogate endpoint and therefore it is
necessary to use data from randomised controlled clinical trials
where culture results during treatment are available as well as
follow up for relapse for a minimum of 18 months. To achieve this
objective, data were used from selected TB clinical trials
conducted by the British Medical Research Council (BMRC)
during the 1970s and 1980s.
Methods
Ethics Statement
This study of past clinical trial data was approved by the ethics
committee of the London School of Hygiene and Tropical
Medicine.
Selection of studies
Individual patient data were available from all TB clinical trials
that were conducted by the BMRC in East Africa and East
Asia[3]. These trials provided much of the evidence for the short
course regimens which are standard treatment today[3,19,20].
The advantage of using data only from BMRC trials is that the
clinical and bacteriological protocols were largely unchanged
throughout the programme of trials and the level of homogeneity
was therefore high. These data are therefore ideal for the
evaluation of culture results during treatment as surrogate
endpoints.
These large multi-centre randomised controlled trials included
high quality laboratory data with frequent follow-up sampling
after the end of treatment on smear positive patients with
pulmonary TB. All trials included regimens comprised of various
combinations of first-line drugs available and recommended for
use today[2]: isoniazid, rifampicin, ethambutol and pyrazinamide,
in addition to two drugs no longer used in first-line regimens:
thiacetazone and streptomycin. From this pool of trials, treatment
arms of duration other than six months (the duration of the WHO-
recommended regimen in use today) have been excluded as were
trials of regimens all with less than 2% relapses as the small
numbers of relapses yield too little information for evaluating
surrogates. The full list of treatment arms included is given in
Table 1.
Clinical and Surrogate Endpoint Definitions
A treatment failure was defined as heavy growth on culture (at
least 20 colonies) at month 5 or 6 and a relapse defined as two
cultures with heavy growth within three consecutive months or
three positive cultures with any growth (one colony or more)
within four consecutive months, following the end of treatment.
The clinical endpoint was a combined endpoint of treatment
failure at the end of treatment or relapse in follow-up hereafter
referred to as poor outcome. In the original publications, these
were usually presented as two separate endpoints, but were
combined in this study in a composite endpoint to reflect the
endpoint currently used in phase III TB trials[5,21,22]. The
bacteriological definitions of treatment failure and relapse were
taken from with the original trial reports[3], with the exception
that ‘heavy growth’ was sometimes defined as at least 5, 10 or 20
colonies. Heavy growth of at least 20 colonies was chosen for
consistency across trials. Default or death from a non-TB cause
during treatment were classified as a missing clinical endpoint. If a
patient was lost to follow-up after a single positive culture, they
were classified as a relapse if no further data were available.
Cultures on solid media during treatment were available
monthly and were recorded on a semi-categorical scale: negative,
0–19 colonies, 20–100 colonies, more than 100 colonies, or
confluent growth. Three endpoints were evaluated as potential
surrogates: i) a positive culture of at least 20 colonies at month one,
ii) a positive culture of any growth at month two and iii) a positive
culture of any growth at month three. Most patients were still
culture positive after one month of treatment, so the endpoint
selected for this time point is a positive culture of at least 20
colonies. Insufficient patients were culture positive at month four
for that to be a useful endpoint.
Statistical Methods
Patients identified as having additional extra-pulmonary TB
were often withdrawn from the trials and so data on treatment
outcomes were often missing. For this reason, this small number of
patients were excluded from the analysis. Patients with negative
cultures at baseline were also excluded.
Culture results during treatment were evaluated as surrogate
endpoints for poor outcome using a two stage approach based on a
frequentist application of the Bayesian methods developed to
evaluate CD4 count as a potential surrogate the development of
AIDS or death[23]. Both stages are repeated for each of the three
candidate surrogates. The first stage involves analysis at the trial
participant-level estimating the treatment effect on the surrogate
endpoint aij (expressed as the log odds ratio of a positive culture)
and the treatment effect on the clinical endpoint bij (expressed as
the log odds ratio of a poor outcome) for each treatment
comparison j, of an experimental arm with the control arm in
each trial i. Many of the trials did not have a pre-specified ‘control
regimen’ and so, unless the control arm was obvious, the arm with
the highest proportion of poor outcomes was identified as the
nominal control. This was done so that the difference in risk of
poor outcome between the experimental and control regimens is
greatest and therefore the treatment ordering is such that the most
amount of information is available for evaluating culture results as
surrogate endpoints. Where two or more arms in a trial had the
same treatment for the first one or two months, the control arm
was selected to limit the number of comparisons of such arms.
The second stage involves analysis at the treatment-comparison-
level fitting a linear regression model with bij as the response and
aij as the explanatory variable. Since the pairs (aij, bij) are
estimated with varying precision, the model is fitted with weights
equal to the inverse of the mean of the variances of the aij and bij
for each i and j. Robust standard errors are used to account for the
clustering of treatment comparisons within trials and the intercept
term in the linear model is constrained to be zero since each
treatment comparison corresponds to comparisons of different
Surrogate Endpoints for Tuberculosis Trials
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treatment regimens and therefore a non-zero intercept has no
meaning. The treatment effect on poor outcome is also plotted
against the treatment effect on the surrogate with the diameter of
the circles corresponding to the precision of the estimates.
Estimates with greater precision, and therefore larger weight in
the linear model, are represented by larger circles. The proportion
of variation in bij explained by aij in this situation is called the trial-
level proportion of variation explained, R2trial. This is an
established metric for evaluating surrogate endpoints[24], and
based on a number of examples of the use of this metric, an
R2trial$0.80 could be considered as evidence for a surrogate being
‘good’ and R2trial$0.95 being ‘very good’[24]. The analyses were
repeated incorporating adjustment for important baseline patient
risk factors (including smear and culture status, pre-treatment drug
resistance, extent of cavitation, weight, age and sex) in the first
stage of the two-stage analysis.
Results
Baseline Characteristics
Table 2 summarises the baseline characteristics of the trials and
patients included in this study. Data were included from 12 trials,
yielding 49 trial arms and 37 total possible treatment comparisons.
Relapse rates and details of the treatment arms can be found
elsewhere[3] along with references of the individual trial reports.
Patients in the Hong Kong trials were more likely to have pre-
treatment resistance to isoniazid (9% overall) or streptomycin
(10%) than in the East African trials, 7% isoniazid resistance and
3% streptomycin resistance. Patients in the East African trials were
much more likely to present with extensive or gross cavitation
(44% overall) than in the Hong Kong trials (5% overall).
Evaluating the candidate surrogates
Treatment for TB is usually described in two phases, the intensive
phase where three to four drugs are given together followed by the
continuation phase where, typically, only two of these drugs are
continued until the end of treatment. Some treatment comparisons
involved regimens with the same drug combination in the first few
months of treatment. These comparisons were therefore excluded
from the evaluation of the one and two month cultures. In
summary, of the 37 total possible treatment comparisons from 49
trial arms, 32 treatment comparisons were used to evaluate a
positive culture of heavy growth at month one, 33 to evaluate the
month two culture result and 35 the month three culture result, as
surrogate endpoints. All treatment comparisons involved substan-
tial changes to the regimen in the first few months.
Figure 1 and the first three rows of Table 3 show the results of
the second stage of the analysis for all trials overall for the three
potential surrogate endpoints.
There is considerable scatter about the fitted line in Figures 1A
and 1B with the proportions of variation explained, R2trial, only
0.36 in each case. This can be interpreted as a weak relationship
between the treatment comparison on the clinical endpoint of a
poor outcome and the treatment comparison on the candidate
surrogate endpoint meaning that it would not be possible to use
the effect of a treatment regimen on the candidate surrogate to
accurately predict the effect of the treatment on the proportion of
poor outcomes.
Apart from the groupings around the origin in figure 1B
(showing no difference between treatment on either endpoint),
there are at least seven points in the lower right quadrants
indicating that the treatment direction on a poor outcome is
opposite to that on the candidate surrogate. The corresponding
treatments would appear to be inferior to the control when
Table 1. List of trials and treatment arms included in this study.
Trial Year of Start Treatment arms included (first regimen nominated as control)
East Africa 1 1970 6SH, 6SHT, 6SHZ, 6SHR
2 1972 6HR, 2SHRZ/4TH, 2SHRZ/4SHZ2, 6SHR
3 1974 2SHR/4TH, 1SHRZ/5TH, 2SHRZ/4TH, 1SHRZ/5SHZ2
4{ 1976 2SHRZ/4H, 2HRZ/4H, 2SHRZ/4HR, 2SHRZ/4HZ, 2SHRZ/4HRZ
5 1978 2SHRZ/4H, 2SHRZ/4HZ, 2SHRZ/4HR
6 1978 2SHRZ/4H, 2SHRZ/4TH
Hong Kong 1 1972 6SHZ2, 6SHZ, 6SHZ3
2 1974 2SHRE/4SHE2, 2SHRZ/4SHZ2, 4SHRZ3/2SHZ2
3 1977 6HRSE3, 6HRZE3, 6HRSZ3, 6HRSZE3, 6HRZE
4* 1979 2HREZ3/4HRE3, 6SHRE3(2wZ1), 6SHRE3, 6SHRE3(4wZ1), 6SHRE3(8wZ3), 6SHRE3(2wZ3), 6SHRE3(8wZ1),
6SHRE3(4wZ3)
Singapore 1 1973 2SHRZ/4HR, 2SHRZ/4HRZ
3 1983 2S(HRZ)C/4HR3, 2(HRZ)C/4HR3, 1S(HRZ)C/5HR3, 1SHRZ/5HR3, 2HRZ/4HR3, 2SHRZ/4HR3
Trial numbering corresponds to numbering in a comprehensive review of all MRC studies[3], where full references for trial report(s) are listed. Trials conducted in East
and Central Africa are listed in Table 1.7, trials conducted in Hong Kong in Table 1.8 and trials conducted in Singapore in Table 1.9 of the review[3].
{This trial was actually of 4 month regimens, but was terminated earlier than planned and patients still on treatment at that time were continued to 6 months of
treatment. The results of those on 6 months of treatment were presented in a later publication[44].
*The results of this trial were never published (personal communication, DA Mitchison) and it is therefore not included in the tables of MRC studies in Fox, Ellard and
Mitchison[3]. For treatment notation: S = Streptomycin, H = Isoniazid, T = Thiacetazone, Z = Pyrazinamide, R = Rifampicin, E = Ethambutol. Where the regimen has
distinct intensive and continuation phases, these are separated by a forward slash with the leading number corresponding to the duration in months. The subscript
indicates the number of doses given weekly; the absence of subscript indicates daily dosing. For example, 2SHRE/4SHE2 consists of a 2 month intensive phase of 4 drugs
given daily followed by a 4 month continuation phase of 3 drugs each given twice-weekly. The subscript C indicates the drugs were given in a combined formulation. In
the fourth Hong Kong study pyrazinamide given once or thrice weekly was added to some of the regimens for the first 2, 4 or 8 weeks. This is indicated by the text in
parentheses where, for example, 4wZ1 indicates that once-weekly pyrazinamide was added only for the first 4 weeks.
doi:10.1371/journal.pone.0063840.t001
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evaluating the candidate surrogate, but superior to the control
when evaluating the proportion of poor outcomes.
There is less scatter about the fitted line in Figure 1C than in
Figures 1A and 1B and this is reflected in a proportion of
explained variation considerably higher at 0.69 and the narrowest
95% confidence interval on the slope. Excluding the clustering
around the origin, there is only one point in the lower right
quadrant and one in the upper left.
Patient-level adjustment for baseline factors
The analyses were repeated incorporating adjustment in the first
stage of the analysis for important baseline patient risk factors
(including smear and culture status, pre-treatment drug resistance,
extent of cavitation, weight, age and sex) with no substantial
differences in the result (data not shown).
Analysis by geographical region
Most of the trials were conducted across two separate
geographical regions: East Africa and Hong Kong. There is
evidence of different relapses rates between clinical trials
conducted in these two regions using the same treatment regimen
on three separate occasions[3]. Therefore, the three candidate
surrogate endpoints were evaluated in trials separately for Hong
Kong and East Africa. The results are shown in Figures 2 and 3
and Table 3. Too few treatment comparisons (all from one trial)
were available from trials in Singapore to draw any clear
conclusions.
At months one and two, analysis restricted to data from East
Africa shows great variation about the line, with the proportion of
variation explained 0.29 and 0.19, respectively, with very wide
confidence intervals. This contrasts with analysis of the month
three culture in East Africa, where there is a clear linear trend
(Figure 2B, proportion of variation explained 0.81).
Six points lie in the lower right quadrant in Figure 2A,
indicating an effect of treatment on the two month culture result
that is in the opposite direction to the effect on the proportion of
poor outcomes. Of these, two correspond to the addition of
rifampicin beyond two months, two to the addition of pyrazin-
amide beyond two months and two to little or no change beyond 2
months.
In contrast to the East African graphs, a linear trend is more
apparent for all months in the graphs restricted to data from Hong
Kong only. At months one and three the proportions of explained
variation are reasonably high at 0.69 and 0.62 respectively though
the widths of the confidence intervals are also very wide. The best
fit is at month two with a narrow 95% confidence interval around
the slope, a high proportion of explained variation at 0.86, and no
points outside the lower left quadrant, except for three which are
very close to the origin (Figure 3A).
Fitting one model allowing for different slopes for trials from
Hong Kong and East Africa, there was no evidence for interaction
with p= 0.46 and p=0.75 for months one and two, respectively.
At month three, there was evidence for a difference in slopes
between trials from Hong Kong and trials from East Africa,
p = 0.015.
Table 4 shows a summary of some of the differences by
geographical region. 73% of the treatment comparisons in the
Hong Kong trials were of two regimens that included rifampicin
throughout compared to only 6% of the treatment comparisons in
the East African trials. Similarly, all of the regimens evaluated in
the East African trials had daily dosing in the intensive phase of
treatment compared to only 7% in the Hong Kong trials and 88%
in the continuation phase in East African trials compared to none
in the Hong Kong trials.
Culture conversion occurred earlier on average in Hong Kong
compared to East Africa. 15% of patients at two months and only
4% of patients at three months were still culture positive in Hong
Kong compared with 29% and 10% respectively in East Africa.
Repeating the analyses for comparisons of two regimens that
contained rifampicin throughout treatment resulted in 0.67 and
0.46 proportion of variation explained for the 2 month and 3
month cultures respectively.
Table 3. Estimates of the slope of the fitted line and of the proportion of explained variation from the model from the second
stage.
Analysis Month of Culturea Trials
Treatment
Comparisonsb Slope (95% CI) R2trial
Overall 1 9 32 1.35 (20.10, 2.80) 0.36
2 9 33 0.85 (0.13, 1.57) 0.36
3 11 35 1.29 (0.82, 1.76) 0.69
East Africa trials only 1 4 13 1.13 (21.82,4.11) 0.29
2 4 13 0.76 (21.57,3.09) 0.19
3 6 16 1.61 (1.38,1.83) 0.81
Hong Kong trials only 1 4 15 1.98 (20.92,4.05) 0.68
2 4 15 0.99 (0.82,1.16) 0.86
3 4 15 0.82 (0.09,1.56) 0.62
Singapore trials only 1 1 4 0.19 (24.95,5.33) ,0.01
2 1 5 20.06 (22.31,2.20) ,0.01
3 1 4 20.52 (25.09,4.05) 0.04
CI - Confidence Interval; R2trial - trial-level proportion of variation.
aThe month 1 endpoint evaluated was a positive culture with heavy growth (at least 20 colonies). The month 2 and 3 endpoints evaluated were a positive culture with
any growth (at least 1 colony).
bDue to similarities in regimens in the first few months of treatment, not all 37 treatment comparisons could be used for each analysis.
doi:10.1371/journal.pone.0063840.t003
Surrogate Endpoints for Tuberculosis Trials
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e63840
Discussion
The two month culture has variously been described as ‘the
main surrogate marker [for sterilizing activity]’[25], a ‘currently
available surrogate marker of relapse rates’[26], ‘probably the best
available surrogate marker for the relapse rate’[27] and ‘an index
of efficacy of anti-TB regimens’[28]. These conclusions are based
on limited published evidence and a varied understanding of what
is meant by a surrogate.
Using the definitions of surrogacy outlined in the introduction,
this study has shown that the two month culture appeared to be a
good surrogate endpoint using data from the Hong Kong trials
and the three month culture was suggestive of a good surrogate
endpoint using data from the East African trials, but the reverse
was not true.
There were no substantial differences in the results on
adjustment for patient-level baseline factors in the first stage of
the analysis. This was not unexpected as each treatment
comparison was a comparison of randomised groups which would
be likely to be reasonably balanced by any baseline risk factors due
to the process of randomisation.
On the one hand, the results are encouraging as they suggest
that culture results over the first few months of treatment can be
an acceptable surrogate endpoint in certain trials in certain
populations. However, it is unclear which populations this would
apply to, as the heterogeneity in results could be due to a number
of factors, not just the geographical location of trial sites.
More of the treatment comparisons in the Hong Kong trials
were of two regimens that included rifampicin throughout and
many regimens included intermittent dosing, even in the intensive
phase of treatment. Culture conversion was also earlier on average
in the Hong Kong trials as compared to the East African trials as
has been noted elsewhere[3], this was probably due at least in part
to the greater use of rifampicin in the Hong Kong trials. Delayed
culture conversion has however been reported in African patients
compared to non-African patients, albeit in liquid media, in a
recent multi-site clinical trial[29]. The authors concluded the
differences could be due to ‘modest variation in laboratory
processes’ but that further investigation was needed to find other
possible causes[29]. Studies have also shown cavitation to be
strong risk factor for relapse[3,14]; and differences have been seen
in relapse rates[30] and culture conversion after eight weeks of
treatment[31] by strain and lineage of M. tuberculosis, with a
corresponding association between strain and ethnicity or
geographical location.
Based on these results, a surrogate endpoint that is a summary
measure of the longitudinal profile of culture results over time is
likely to be more useful than a culture result at a single time point.
Two approaches for capturing the longitudinal profile of culture
results that have been proposed are (i) using a parameter from
repeated measures modelling of culture results over time or (ii)
summarising the time to stable culture conversion in a survival
analysis. These approaches have been described elsewhere[32].
Both have been used in phase II TB clinical trials that are
completed[33,34] and ongoing (the former in the TB Alliance
study NC-002, clinicaltrials.gov identifier NCT01498419 and the
latter in PanACEA MAMS-TB, Pan African Clinical Trials
Registry identifier PACTR201205000383208). There is, however,
no evidence as yet that either approach will yield markers that are
acceptable surrogate endpoints.
Cultures were only performed monthly in the BMRC trials and
therefore neither repeated measures modelling nor an analysis of
time to stable culture conversion can be conducted with these
data. Data from multiple treatment comparisons across large
Figure 1. Analysis of culture results as surrogate endpoints
across all trials. A. Month 1 (a positive culture with heavy growth, at
least 20 colonies), R2trial = 0.36. B. Month 2 (a positive culture with any
growth), R2trial = 0.36. C. Month 3 (a positive culture with any growth),
R2trial = 0.69. Logs odds ratio of a poor outcome plotted against log
odds ratio of a positive culture. Fitted line is weighted by the precision
of the estimates, and this precision is represented by the diameter of
the circles around each point. The dotted line represents the 95%
confidence interval on the slope.
doi:10.1371/journal.pone.0063840.g001
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multi-centre trials will be necessary for a formal evaluation of a
marker as a surrogate endpoint. Some data will become available
in the next few years as a several large phase III clinical trials will
be finishing and reporting results. Adaptive trial designs and
innovative clinical development pathways are critical to compen-
sate for the current lack of suitable surrogate endpoints[35].
In the only other formal evaluation of any marker as a surrogate
endpoint for treatment response in TB[36], the authors evaluated
two month culture conversion as a surrogate endpoint using data
from published report of trials conducted by the BMRC. They
selected 30 pairs of regimens showing that the slope of the meta-
regression line ‘was statistically significant (p,0.00001)’. There is
some spread around the fitted line, but the authors do not give a
figure for the R2trial to allow the reader to judge whether this
analysis shows two month culture conversion to be an acceptable
surrogate. The authors concluded that two month culture
conversion ‘should be a surrogate endpoint for the registration
of new drugs for the treatment of TB.’ They were, however,
unable to evaluate culture status at any other time as a surrogate,
as it was only common in trial reports to publish the two month
culture conversion rates, and there was no evidence that they had
looked at effect modification by geographical region.
Figure 2. Sub-group analysis by geographical region: East African trials. A. Month 2 restricted to East African trials, R2trial = 0.19. B. Month 3
restricted to East African trials, R2trial = 0.81. Logs odds ratio of a poor outcome plotted against log odds ratio of a positive culture. Fitted line is
weighted by the precision of the estimates, and this precision is represented by the diameter of the circles around each point. The dotted line
represents the 95% confidence interval on the slope.
doi:10.1371/journal.pone.0063840.g002
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Limitations
Apart from the limitation of the cultures only being available
monthly, the cultures were done on solid media which is being
used increasingly less in clinical trials. The results may well be
different when liquid media are used due to the increased
diagnostic sensitivity[21].
These trials were conducted before methodology was available
to distinguish true endogenous relapse from exogenous reinfection
caused by a new strain of M. tuberculosis. It is therefore possible that
a number of the cases recorded as relapses were in fact as a result
of reinfection. However, this number is likely to be few for two
reasons. Firstly reinfections occur more frequently in HIV co-
infected patients[37,38] and these trials were conducted before the
HIV epidemic. Secondly, and more importantly, many of these
trials had up to 5 years of follow-up finding very few recurrences in
the final 2–3 years of follow-up. Results at 5 years were consistent
with those after 30 months suggesting minimal impact of the
inclusion of possible cases of exogenous reinfection[3].
The two-stage analysis methodology did have some drawbacks.
The estimates of the aij were assumed in the second stage to be
without error with the variance of the estimates only entering the
model through the weights. The aij and bij are estimated
separately in the first stage and the correlation between the two
Figure 3. Sub-group analysis by geographical region: Hong Kong trials. A. Month 2 restricted to Hong Kong trials, R2trial = 0.86. B. Month 3
restricted to Hong Kong trials, R2trial = 0.62. Logs odds ratio of a poor outcome plotted against log odds ratio of a positive culture. Fitted line is
weighted by the precision of the estimates, and this precision is represented by the diameter of the circles around each point. The dotted line
represents the 95% confidence interval on the slope.
doi:10.1371/journal.pone.0063840.g003
Surrogate Endpoints for Tuberculosis Trials
PLOS ONE | www.plosone.org 8 May 2013 | Volume 8 | Issue 5 | e63840
is therefore assumed to be zero, which is probably not the case
since the estimates are from the same group of trial participants.
This will result in estimates of R2trial slightly above or below the
true values, but the impact is likely to be minimal.
All comparisons were of two treatments with differences in the
first few months of treatment. Many comparisons also involved
changes in regimens after the putative surrogate endpoint had
been measured. Of the six points in the lower right quadrant of
Figure 2A, evaluating the 2 month culture in East African trials,
two were of comparisons where rifampicin was added beyond two
months. Trials have shown that rifampicin throughout treatment is
critical[39], but this cannot be reflected in the two month culture
result. Restricting the analysis to all comparisons of two regimens
that contained rifampicin throughout treatment gives considerably
better results for the two month culture (R2trial = 0.67 compared to
R2trial = 0.36), but not as good as in the sub-group of Hong Kong
trials only (R2trial = 0.86).
Fundamentally, a marker that is measured before the end of
treatment cannot capture the full effect of the treatment regimen
and can never therefore be a perfect surrogate. This can be
illustrated in a trial comparing a six month regimen with
rifampicin throughout with an eight month regimen with
rifampicin for only the first two months[39]. The two-month
intensive phase was unchanged and therefore the proportion of
culture positive patients at two months was similar (17% and 14%
respectively) but the proportion with unfavourable outcomes at the
end of follow-up was significantly different (5% and 10%
respectively, p,0.01). The optimum time for measuring a marker
that could be a surrogate at the end of treatment. Unlike the
situation in HIV where CD4 count or viral load can always be
measured, TB patients are almost without exception negative on
culture at the end of treatment (unless they have failed treatment
or have an uninformative isolated positive) and therefore it is likely
that more sensitive methodologies that can detect the presence of
M. tuberculosis later in treatment will be needed. These could
include a molecular viable count assay[40], resuscitation-promot-
ing factors[41] or cycle threshold of the Xpert MTB/RIF
assay[42,43].
Conclusions
Without a better understanding of the main cause of the
heterogeneity of results, neither the two month nor the three
month culture on solid media can be recommended for use as the
primary endpoint in a phase III clinical trial - the ultimate
objective for a putative surrogate.
The results are encouraging, however, in that culture results on
solid media during treatment capture a moderate proportion of
the treatment effect on long-term outcome and are appropriate as
endpoints for phase II trials to identify promising regimens to take
forward to phase III for more rigorous evaluation. An endpoint
that is a summary measure of the longitudinal profile of culture
results over time or that is able to detect the presence of M.
tuberculosis later in treatment is more likely to be a better endpoint
for a phase II trial than a culture result at a single time point and
may prove to be an acceptable surrogate. More data are needed
before any endpoint can be used as a surrogate in a confirmatory
phase III trial.
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